ESPR - Esperion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
146,401
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
180,120
171,488
147,603
57,868
29,802
Selling General and Administrative
45,861
33,097
21,379
18,282
20,238
Total Operating Expenses
225,981
204,585
168,982
76,150
50,040
Operating Income or Loss
-79,580
-204,585
-168,982
-76,150
-50,040
Interest Expense
-
100
198
376
520
Total Other Income/Expenses Net
2,888
2,775
2,192
1,548
776
Income Before Tax
-76,792
-201,810
-166,988
-74,978
-49,784
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-76,792
-201,810
-166,988
-74,978
-49,784
Net Income
-76,792
-201,810
-166,988
-74,978
-49,784
Net Income available to common shareholders
-76,792
-201,810
-166,988
-74,978
-49,784
Reported EPS
Basic
-
-7.54
-6.98
-3.33
-2.26
Diluted
-
-7.54
-6.98
-3.33
-2.26
Weighted average shares outstanding
Basic
-
26,754
23,933
22,544
22,020
Diluted
-
26,754
23,933
22,544
22,020
EBITDA
-
-204,585
-166,790
-74,602
-49,264